Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
M Adoración
MA
Martín-Gómez
Sergio A
SA
García-Marcos
Mercedes
M
Caba-Molina
M Eugenia
ME
Palacios-Gómez
Mercedes
M
Gómez-Morales
Carlos
C
Claver-Ferré
D058186:Acute Kidney Injury / Q000097:blood / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D000740:Anemia / Q000209:etiology; D001706:Biopsy; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D016903:Drug Monitoring / Q000379:methods; D057915:Drug Substitution; D021501:Flank Pain / Q000209:etiology; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D009194:Myeloma Proteins / Q000032:analysis*; D011719:Pyrazines / Q000008:administration & dosage; D006435:Renal Dialysis / Q000295:instrumentation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
D001897:Boronic Acids; D007145:Immunoglobulin kappa-Chains; D009194:Myeloma Proteins; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide